The role of dopaminergic agonists in congestive heart failure.
Congestive Heart Failure is a clinical syndrome characterised by myocardial dysfunction and sympathetic activation. Plasma norepinephrine (NE) levels have been related to the poorest survival. Large-scale clinical trials have proved the clinical benefits of Angiotensin Converting Enzyme inhibitors in reducing the risk of death and hospitalisation. However, mortality remains high in the treated group underlining the need to explore new therapeutic approaches. Specific activation of peripheral dopamine receptors exerts profound hemodynamic effects and neurohormonal control such as peripheral and renal vasodilation, diuresis and natriuresis and inhibition of NE release. Z1046, a mixed D1/D2-like agonist, reduces peripheral and renal vascular resistance increasing renal blood flow. In anaesthetised dogs the compound strongly reduces plasma NE without increasing plasma renin activity and plasma aldosterone. The inhibition of NE could be the basis of Z1046 potent cardioprotective effect observed in a dog model of myocardial ischemia and reperfusion, in which the severity of ventricular arrhythmias was markedly reduced, resulting in higher survival. These findings suggest that chronic oral treatment with specific dopaminergic agonists is able to alleviate the hemodynamic burden on the myocardium, and to suppress the sympatho-adrenal activity.
Semeraro
C
C
Zambon Group S.p.A. Bresso, Milan, Italy.
Marchini
F
F
Ferlenga
P
P
Masotto
C
C
Morazzoni
G
G
Pradella
L
L
Pocchiari
F
F
D000818:Animals; D004285:Dogs; D018491:Dopamine Agonists / Q000494:pharmacology* / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D009284:Naphthols / Q000494:pharmacology*; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology
D018491:Dopamine Agonists; D009284:Naphthols; D011954:Receptors, Dopamine; C105333:Z1046